You just read:

BioMarin's Investigational Gene Therapy for Hemophilia A at 6e13 vg/kg Dose Maintains Average Factor VIII Levels within Normal Range for over One Year

News provided by

BioMarin Pharmaceutical Inc.

Jul 11, 2017, 03:30 ET